04 December 2017 ICFO teams up with Accelerate Diagnostics


Lluis Torner, Director ICFO and Joan Martín, VP and Head of EMEA , Accelerate Diagnostics

Signature of collaboration agreement ICFO and Accelerate Diagnostics, S.L. have signed an agreement establishing a framework to explore scientific and technological fields of common interest. Through this agreement, Accelerate Diagnostics, S.L. will have access to state-of-the-art Biology Lab facilities and equipment housed within ICFO for, amongst other things, quality control testing of company products and employee training.

The ICFO Biology Lab is a transversal facility that aims to provide scientific assistance and technical support for researchers’ needs in biological sample handling, preparation and maintenance. The facility meets biosafety level 2 regulations and is equipped with tools and technology to facilitate research activities employing classical and next-generation microbiology, molecular biology and biochemistry techniques for in vitro and in vivo applications.

Accelerate Diagnostics, S.L. is an in vitro medical diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company’s parent organization, Accelerate Diagnostics, Inc. of Tucson, Arizona, USA, recently obtained FDA marketing authorization for antimicrobial susceptibility testing direct from positive blood culture samples using its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit. The system and kit leverage proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. Recent market studies suggest the solution offers results 1-2 days faster than conventional methods for analyzing blood samples, enabling clinicians to optimize antibiotic selection, dosage, and infusion strategy specific to the individual patient and their infection. To learn more about the Accelerate Diagnostics Group of companies, visit axdx.com

. The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond-shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

Back